Elanco Animal Health Incorporated (ELAN) shares rallied 12.6% in the last trading session to close at $9.38. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This company is expected to post quarterly earnings of $0.31 per share in ...

Core Viewpoint - Elanco Animal Health Incorporated will announce its first quarter 2025 financial results on May 7, 2025, and will hold a conference call to discuss the performance with the investment community and media [1][2]. Company Overview - Elanco Animal Health is a global leader in animal health, focusing on innovating and delivering products and services for the prevention and treatment of diseases in farm animals and pets [3]. - The company has a 70-year heritage in animal health and aims to create value for farmers, pet owners, veterinarians, stakeholders, and society [3]. - Elanco is committed to improving animal health while making a meaningful impact on local and global communities, driven by its vision of "Food and Companionship Enriching Life" and sustainability pillars [3].

GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders: John P. (JP) Bilbrey, Kathy Turner and Craig Wallace have each informed the Board they will not stand for re-election at the conclusion of their terms at the 2025 Annual Meeting of Shareholders. William F. (Bill) Doyle has resigned from the Board, effective immediately, in ...

Core Insights - Elanco Animal Health reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a reported basis but a 4% organic constant currency growth, surpassing the consensus estimate of $1.01 billion [1] - The company reported adjusted EPS of 14 cents, an increase from 8 cents year-over-year, but fell short of the consensus estimate of 15 cents [1] Pet Health Segment - Pet Health revenue reached $439 million, reflecting a 6% year-over-year increase, with a 3% price increase contributing to this growth, driven by strong performance in the global over-the-counter retail parasiticide business and new products like Zenrelia and Credelio Plus, although competitive pressures in the U.S. veterinary channel partially offset these gains [2] Farm Animal Segment - Farm Animal revenue was $570 million, showing a 7% decrease on a reported basis but a 2% increase on an organic constant currency basis, with a 3% contribution from price in the fourth quarter; strong demand for Experior and Rumensin in the U.S. and swine across multiple geographies supported the organic growth [3] Financial Metrics - Adjusted EBITDA was $177 million, marking a 7% increase, with an adjusted EBITDA margin of 17.4%, up 150 basis points [3] Future Guidance - For 2025, Elanco expects revenues between $4.45 billion and $4.51 billion, slightly below the consensus of $4.53 billion, and adjusted EPS in the range of 80-86 cents, compared to the consensus of 90 cents; the company anticipates a revenue headwind of approximately $110 million due to unfavorable foreign exchange rates [4] Management Commentary - The company is focused on accelerating organic constant currency revenue growth for 2025 and improving earnings potential while navigating a dynamic macroeconomic environment; adjustments made were primarily for incremental currency headwinds [5] Q1 2025 Expectations - For the first quarter of 2025, Elanco projects revenues of $1.16 billion to $1.18 billion, below the consensus of $1.21 billion, and adjusted EPS of 29-34 cents, compared to the consensus of 30 cents [6] Stock Performance - Elanco's stock is down 4.68% at $10.59 as of the last check on Tuesday [7]

D 2024 Earnings – Fourth Quarter February 25, 2025 2024 | Q4 Earnings Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and first quarter guidance, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance ...

Elanco Animal Health Incorporated (NYSE:ELAN) Q4 2024 Earnings Conference Call February 25, 2024 8:00 AM ET Company Participants Tiffany Kanaga - Head of IR Jeffrey Simmons - President & CEO Todd Young - EVP & CFO Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Daniel Clark - Leerink Partners Andrea Alfonso - UBS Erin Wright - Morgan Stanley Balaji Prasad - Barclays Mike DiFiore - Evercore ISI Chris Schott - JPMorgan David Westenberg - Piper Sandler Operator Ladies and ...

Elanco Animal Health Incorporated (ELAN) reported $1.02 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 1.5%. EPS of $0.14 for the same period compares to $0.08 a year ago.The reported revenue represents a surprise of +0.83% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being $0.15, the EPS surprise was -6.67%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expe ...

Core Viewpoint - Elanco Animal Health reported quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share, but showing an improvement from $0.08 per share a year ago, indicating a -6.67% earnings surprise [1] Financial Performance - The company posted revenues of $1.02 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.83%, although this represents a decline from year-ago revenues of $1.04 billion [2] - Over the last four quarters, Elanco has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Elanco shares have declined approximately 8.3% since the beginning of the year, contrasting with the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.31 on revenues of $1.2 billion, and for the current fiscal year, it is $0.89 on revenues of $4.51 billion [7] Industry Outlook - The Medical - Outpatient and Home Healthcare industry, to which Elanco belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2500 INNOVATION WAY, GREENFIELD, INDIANA 46140 (Address an ...

Revenue Performance - Fourth quarter 2024 revenue was $1,020 million, a decrease of 1% on a reported basis and an increase of 4% on an organic constant currency basis[6]. - Full year 2024 revenue was $4,439 million, flat to the prior year on a reported basis and up 3% on an organic constant currency basis[3]. - Pet Health revenue for the fourth quarter was $439 million, a 6% increase on both a reported and organic constant currency basis[7]. - Farm Animal revenue for the fourth quarter was $570 million, a 7% decrease on a reported basis but a 2% increase on an organic constant currency basis[8]. - Revenue for Q4 2024 was $1,020 million, a decrease of 1.5% compared to $1,035 million in Q4 2023[36]. - Full year revenue for 2024 was $4,439 million, an increase of 0.5% from $4,417 million in 2023[36]. - Full year 2025 revenue guidance is set between $4,445 million and $4,510 million, with an estimated foreign exchange headwind of $110 million[18]. - The innovation revenue target for 2025 has been raised to between $640 million and $720 million[18]. Profitability and Loss - Adjusted EBITDA for the fourth quarter of 2024 was $177 million, representing 17.4% of revenue, an increase of 7% compared to the fourth quarter of 2023[16]. - Adjusted net income for Q4 2024 was $80 million, compared to an adjusted net income of $180 million in Q4 2023[43]. - The reported net loss for the fourth quarter of 2024 was $8 million, compared to a net loss of $141 million in the same period of 2023[15]. - Basic loss per share for Q4 2024 was $(0.02), improving from $(0.29) in Q4 2023[36]. - Adjusted EBITDA for the twelve months ended December 31, 2024, was $910 million, down from $979 million in 2023, resulting in an adjusted EBITDA margin of 20.5% compared to 22.2%[55]. - The company reported a diluted EPS of $0.68 for the year ended December 31, 2024, compared to a loss of $2.50 in 2023, marking a significant turnaround[52]. - Total adjustments to diluted EPS for the year ended December 31, 2024, amounted to $0.23, while for 2023, it was $3.39, indicating a significant reduction in adjustments year-over-year[52]. Cash Flow and Debt - The company generated over $500 million in operating cash flow for 2024, doubling from the prior year[3]. - The company reported a net debt of $2,500 million, with a net leverage ratio of 3.5x trailing twelve month adjusted EBITDA[32]. - The total gross debt as of December 31, 2024, was $4.349 billion, with a net debt of $3.881 billion after accounting for cash and cash equivalents of $468 million[57]. Future Guidance and Expectations - The company expects operating expenses to increase approximately 6% year over year in constant currency for 2025, driven by strategic investments in innovation[19]. - The company plans to continue focusing on product development and market expansion strategies to drive future growth[26]. - Elanco is committed to enhancing its research and development efforts to innovate in animal health technologies[28]. - The company expects to continue focusing on restructuring and integration efforts to improve operational efficiency and financial performance in the upcoming quarters[59]. - 2025 full year reported EPS guidance ranges from $(0.05) to $0.01, with adjusted EPS expected to be between $0.80 and $0.86[60]. - Reported net (loss) income for 2025 is projected to be between $(25) million and $7 million, with adjusted EBITDA guidance ranging from $830 million to $870 million[62]. - First quarter 2025 reported EPS guidance is between $0.03 and $0.08, while adjusted EPS is expected to be between $0.29 and $0.34[63]. - First quarter 2025 reported net income is projected to be between $13 million and $41 million, with adjusted EBITDA guidance ranging from $240 million to $260 million[65]. - Adjusted EBITDA margin for 2025 is expected to be between 18.7% and 19.3%[62]. - Adjusted EBITDA margin for the first quarter of 2025 is projected to be between 21.0% and 22.2%[65]. - Total adjustments to EPS for 2025 full year are estimated at $0.85[60]. - Non-GAAP adjustments for 2025 full year include asset impairment and restructuring charges of approximately $20 million[62]. - Amortization of intangible assets for 2025 full year is approximately $1.02 million[60]. - Tax impact of adjustments for 2025 full year is estimated to be between $(0.25) and $(0.24) million[60].